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ABSTRACT

INTRODUCTION
Several distinct obstructive airway diseases share a phenotype of thickened mucus and/or mucostasis, including chronic rhinosinusitis (CRS) (1), cystic fibrosis (CF), asthma (2, 3) , and COPD (4).
In conducting airways from the nasal turbinates down to small bronchi ~1 mm 2 in diameter, a large percentage of airway surface liquid (ASL) and mucus is generated in airway submucosal exocrine glands (5) (6) (7) . Submucosal gland serous acinar cells are sites of expression of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) Cl -channel (8) (9) (10) (11) (12) . Defects in CFTR-dependent serous cell secretion likely play an important role in CF pathology, supported by observations of occluded mucus-filled gland ducts, gland hypertrophy and hyperplasia, and gland infection in lungs of CF patients (13, 14) . Intact glands from CF individuals or transgenic CF animals secrete less fluid in response to cAMP-elevating agonists such as vasoactive intestinal peptide (VIP) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) compared with non-CF glands. Gland hypertrophy, duct plugging, and/or excess mucus secretion have also been observed in COPD and asthma (4, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) , with gland hypertrophy being greater in fatal asthma cases than non-fatal cases (33) .
Proper gland secretion likely requires bicarbonate (HCO3 -) secretion by serous cells at the distal ends of the glands to facilitate polymerization of mucins secreted by more proximal mucous cells (36) (37) (38) (39) (40) (41) ( Figure 1A) . However, the mechanisms by which serous cells secrete HCO3 -are unknown. HCO3 -may also be critical to the efficacy of antimicrobial peptides secreted by serous cells (42) (43) (44) (45) , including lysozyme, lactoferrin, LL-37, and Muc7 (46) . Understanding how airway glands secrete HCO3 -may yield insights into the pathophysiology of CRS, CF, COPD, and asthma, all of which have a common phenotype of altered airway mucus secretion or rheology.
We previously developed live cell imaging techniques to study living primary mouse nasal serous cells and demonstrated that they secrete HCO3 -during cholinergic stimulation (47) . Cholinergic-induced secretion is largely intact in CF (10-12, 15-24, 46-48) , as it is mediated by Ca 2+ activated Cl -channels, including TMEM16A (12) . An initial goal of the current study was to directly test if serous acinar cells secrete HCO3 -during stimulation with VIP, whether this occurs through CFTR, and if activation of TMEM16A could substitute. A further goal was to understand the potential relationship of VIP and neuropeptide Y (NPY), both upregulated in inflammatory airway diseases, in control and composition of airway gland secretions. A recent review highlighted a need for a clearer portrait of neuropeptide regulation of submucosal gland secretion within the context of the diverse lung diseases characterized by mucus obstruction (49) .
Parasympathetic VIPergic neurons (50) (51) (52) (53) (54) (55) and NPY-containing fibers (56) (57) (58) are exist in the respiratory tract, with some nerves co-expressing VIP and NPY (59) , including in the proximity of submucosal glands (60, 61) . Immune cells like activated macrophages (62) (63) (64) or epithelial cells (65) can also make NPY. Elevated NPY in allergic asthma (66, 67) may link psychological stress with asthma exacerbations (68) (69) (70) . Both VIP-containing and NPY-containing nerves may be increased in mucosa from patients with allergic rhinitis (71, 72) or irritative toxic rhinitis (73) . VIP and NPY, but not substance P or calcitonin gene-related peptide (CGRP), are found in the pedicle of nasal polyps, suggesting they may play a role in polyp formation (74) . Mice lacking NPY or NPY1R have reduced allergic airway inflammation (75) , suggesting this neuropeptide and this receptor isoform detrimentally contribute to inflammatory airway diseases. One study found NPY and NPYR1 expression elevated in mouse lungs after influenza infection; knockout of NPY reduced the severity of disease and lowered IL-6 levels (63).
In other studies outside the airway, NPY deficiency can reduce Th2 responses (76, 77) .
The role of VIP as a cAMP-dependent activator of gland secretion has been extensively studied (11, 19, 78) , but the role of NPY is less clear. A cocktail of NPY and norepinephrine inhibited cultured tracheal gland cell glycoprotein secretion (79) , and NPY inhibits bulk mucus secretion in ferret trachea (80) , though there is little mechanistic data for how NPY affects epithelial or gland cells specifically. We sought to understand how VIP and NPY signaling may interact to control of gland serous cell secretion.
Because NPY receptors are often Gi-coupled, they may reduce cAMP-evoked responses to Gs-coupled VIP or beta-adrenergic receptors (81) (82) (83) or CCK receptors (84) . We hypothesized that NPY may reduce airway serous cell fluid and/or HCO3 -secretion during VIPergic stimulation though modulation of cAMP and thus CFTR. Moreover, VIP and NPY are potent immunomodulators in the gut (85) . These peptides may be relevant for airway gland-cell-driven inflammation which may help drive airway submucosal remodeling or airway inflammation.
We examined the effects of VIP and NPY on secretion from primary human airway gland serous acinar cells isolated from nasal turbinate. Cells were studied acutely as well as in an air-liquid interface (ALI) culture model that retained expression of important serous cell markers and facilitated polarized studies and co-culture with human immune cells. Results below contribute to our understanding of airway serous cell secretion and the role of CFTR in both secretion and inflammation, also suggesting therapeutic strategies (NPY1R antagonists, TMEM16A activators) for obstructive inflammatory airway diseases.
RESULTS
VIP stimulates both Cl -and HCO3 -secretion from airway gland serous cells through CFTR
Submucosal gland acini and single acinar cells ( Figure 1B) were isolated from human nasal middle turbinate as previously described (11) . Serous acini exhibited secretory-granule localized immunofluorescence for serous cell marker lysozyme ( Figure 1C ; as previously reported (10, 12, 48) ) as well as basolateral immunofluorescence of VIP receptors VIPR1 (VPAC1; Figure 1D ) and VIPR2 (VPAC2; Figure 1E ). In contrast, secretory Cl -channels TMEM16A and CFTR exhibited apical membrane immunofluorescence ( Figure 1F-G) , as previously observed (10, 12, 48) .
Fluid and ion transport pathways were studied in acutely isolated serous cells using simultaneous Figure 2B ), as we previously reported (11) . We now found this was also accompanied by a transient decrease in intracellular pH (pHi) followed by a more sustained increase in pHi ( Figure 2C-D) .
Both the cell shrinkage and decrease in pHi were absent in cells isolated from CF patients (Figure 2C-D) . The agonist-evoked pHi decrease was absent when HCO3 -was removed from the media (Supplemental Figure 1A-C) , and the secondary pHi increase was blocked with inhibition of the Na + HCO3 -co-transporter (NBC; Supplemental Figure 1D ). This suggests the transient pHi decrease reflects HCO3 -efflux during activation of secretion, while the pHi increase reflects activation of NBC, sustaining HCO3 -secretion by keeping intracellular HCO3 -high. This is similar to cholinergic evoked pHi decreases and subsequent elevation of pHi by Na + /H + exchangers (NHEs) in mouse nasal serous cells (47) , but reveals an important mechanistic difference between cAMP and Ca 2+ pathways.
The pHi decrease was also blocked by eliminating the driving forces for HCO3 -efflux using ion substitution (Supplemental Figure 1E) , suggesting the pHi decrease is mediated by conductive HCO3 -efflux, such as an ion channel. Both forskolin-induced pHi decrease and cell volume decrease were inhibited by CFTRinh172 (10 µM; Figure 2E ). VIP-induced cell volume and pHi decreases were blocked by CFTRinh172 or K + channel inhibitors clofilium and clotrimazole (30 µM each; Figure 2F) In contrast, cholinergic agonist carbachol (CCh; 10 µM), which activates Ca 2+ -driven TMEM16A-mediated secretion (10) (11) (12) 46) , stimulated cell shrinkage and pHi decreases that were blocked by TMEM16A inhibitors NFA, T16Ainh-A01, CaCCinh-A01 ( Figure 2G ). CCh-induced responses were intact in cells from CF patients ( Figure 2H) . Activation of TMEM16A with a pharmacological activator (Eact; 25 µM) was sufficient to restore both Cl -(shrinkage) and HCO3 -(pHi) secretion responses to VIP in cells from CF patients ( Figure 2H ). In summary, our data suggest serous cell shrinkage during VIP stimulation reflects secretion of both Cl-and HCO3-directly through CFTR ( Figure 2I ).
NPY reduces CFTR-mediated serous cell fluid and HCO3 -secretion during VIP stimulation
Beyond the histological observations described above regarding NPY in airways, we also noted that Calu-3 cells, a bronchial adenocarcinoma line frequently used as a serous cell surrogate due to high CFTR and lysozyme expression, express relatively high amounts of NPY1R relative to other airway cancer lines according to public gene expression databases (Supplemental Tables 1 and 2 ). This may be an artifact of Calu-3 cells being cancer cells, but we decided to test for NPY receptor function in primary serous cells.
We observed no secretory responses to 100 nM NPY (Figure 3A) , but the magnitude of VIPevoked pHi decreases and cell shrinkage were reduced after NPY (Figure 3A-B) . As a control, a scrambled NPY peptide had no effect ( Figure 3B) Figure 3C-D) . In the presence of CFTRinh172, anion permeability was markedly reduced and NPY had no effects ( Figure 3D ), suggesting that NPY directly reduces VIP-stimulated CFTR permeability.
CFTR is activated by PKA downstream of cAMP. We imaged cAMP changes in nasal serous cells in real time using a fluorescent mNeonGreen-based cAMP biosensor (cADDis (94)). 1 µM VIP induced a rapid and reversible increase in cAMP (decrease in cADDis fluorescence) that was blocked by VIPR antagonist VIP6-28 (1 µM; Figure 4A -B). The cAMP increase was independent of Ca 2+ , as it was not blocked by intracellular and extracellular calcium chelation ( Figure 4C ). Interestingly, we also found no differences in the ability of VIP to increase cAMP in Wt or CF cells (Supplemental Figure 3) , in contrast to previous hypotheses that cAMP signaling may be defective in CF cells (95) . However, NPY (100 nM) significantly reduced the cAMP responses to 0.5 µM and 5 µM VIP ( Figure 4D-E) ; the effects of NPY were eliminated in the presence of a NPY1R antagonist BIBO 3304 (5 µM) or in cells treated with pertussis toxin (PTX), which ADP-ribosylates and inactivates Gi proteins (Figure 4D-E ). These data demonstrate that NPY reduces cellular anion efflux through CFTR to blunt Cl -, HCO3 -, and fluid secretion from these cells.
To facilitate polarized studies of serous cells, we used previously published culture methods for gland acinar cells that preserve a serous phenotype (96) (97) (98) . Serous cells cultured at air liquid interface (ALI) expressed serous marker Muc7 (99), VIP1R, and VIP2R by Western ( Figure 5A ). Mucous maker Serous cell ALIs were incubated in the presence of unstimulated or PMA-stimulated MFs as above and ASL pH was measured 2 hours later. ASL pH was not different in the presence or absence of unstimulated MFs, but PMA-stimulated MFs reduced steady-state ASL pH ( Figure 6G ). This effect was inhibited by an NPY1R antagonist (BIBO 3304; 1 µM) and pH was also increased by addition of VIP (1 µM) ( Figure 6G ). Effects of NPY on HCO3 -secretion were verified using a real-time HCO3 -secretion assay using larger apical volumes of SNARF-1-dextran, which confirmed secretion was dependent on apical CFTR (Supplemental Figure 8 ).
NPY inhibits VIP-evoked increases in serous cell antimicrobial peptide secretion
Serous cells secrete a variety of antimicrobial peptides, and secretion can involve cAMP. It is likely that the same stimuli that activate fluid secretion likely activate protein secretion, which is also driven by Ca 2+ and cAMP (103, 104) . To test if NPY can reduce VIP-induced secretion of antimicrobials,
we measured secreted levels of lysozyme, Muc7, and b-defensin 1 (hbD1). Cells were stimulated basolaterally with forskolin (5 µM) or VIP (1 µM) in the presence or absence of NPY or scrambled NPY (100 nM). Forskolin and VIP both increased secretion of lysozyme, Muc7, and bD1, and this was reduced by NPY ( Figure 7A ).
VIP increases bactericidal activity of serous cell secretions while NPY reduces it
Carbonate and/or HCO3 -has been reported to enhance antimicrobial activity of airway antimicrobial secretions (45, 105) . We did observe a small effect of HCO3 -on antimicrobial activity of secretions produced by Calu-3 bronchial serous-like cells (Supplemental Figure 9 ). However, we hypothesized that NPY might have more profound effects on antimicrobial activity through inhibition of 
NPY has pro-inflammatory effects in primary serous acinar cells
Both VIP and NPY have immunomodulatory roles in many tissues (106) (107) (108) (109) , including VIP having anti-inflammatory or protective effects in parotid acini (106, (110) (111) (112) (113) and NPY having proinflammatory effects in leukocytes (85) . Acinar cells from parotid and pancreatic exocrine glands can make and release cytokines (114) (115) (116) (117) . Infection of isolated human tracheal submucosal gland cells with rhinovirus, which can activate TLR3 (118), increases IL-1a, IL-1b, IL-6, and IL-8 (119) . TLR4 is also expressed in pig tracheal acinar cells (120) , and submucosal TLR4 levels may be elevated in CF (121) .
We hypothesized that airway gland cells may be an overlooked significant contributor to the airway cytokine milieu, and this may be modulated by VIP and/or NPY.
In primary nasal serous cell ALIs, the TLR4 activator lipopolysaccharide (LPS) and TLR3
activator poly(I:C) induced secretion of IL-6, TNFa, IL-1b, and granulocyte macrophage colony stimulating factor (GMCSF (Supplemental Figure 11 ). TLR2 activator lipotechoic acid (LTA) also increased secretion of IL-6 and TNFa, while TNFa itself increased secretion of IL-1b and GM-CSF (Supplemental Figure 11) . Furthermore, a type 2 inflammatory cocktail of IL-4 and IL-13 (122) also increased secretion of GM-CSF (Supplemental Figure 11) . Airway gland serous cells can thus respond to and secrete a variety of inflammatory cytokines.
While NPY or VIP had no effect alone on IL-6, TNFa, or GMCSF, NPY increased IL-1b production ~2-fold and significantly increased cytokine production (~50%) during LPS, LTA, IL-4+IL-13, and TNF-a (Supplemental Figure 11 ) stimulation. Effects of NPY were blocked by pertussis toxin, implicating a GPCR Gi-coupled pathway. In contrast, VIP slightly reduced cytokine secretion (25-50%) when combined with inflammatory stimuli, while these reductions were eliminated in the presence of NPY (Supplemental Figure 11) . Together, these data suggest that VIP has a small anti-inflammatory effect while NPY is pro-inflammatory when combined with a broad range of stimuli.
A strong Th2 environment by itself may increase other inflammatory responses in airway cells (123) . Co-stimulation with IL-4+IL-13 increased IL-6 and GM-CSF secretion in response to either poly(I:C) or LPS, and this was enhanced further in the presence of NPY (Supplemental Figure 12A) , suggesting that NPY is pro-inflammatory even within the context of elevated IL-4 and IL-13 in inflammatory airway diseases. To validate results from cultured cells, we incubated freshly dissociated primary serous celsl seeded at high density with TNFa or poly(I:C) ± NPY or scrambled NPY for 18
hours. TNFa and poly(I:C) increased secretion IL-33, GM-CSF, or IL-6, and this was enhanced by NPY but not scrambled NPY (Supplemental Figure 12B) , supporting that airway gland serous cells can secrete several cytokines involved in allergy, asthma, and chronic rhinosinusitis, and confirming NPY is pro-inflammatory.
We examined cytokine release in response to heat-killed clinical CRS isolates of gram negative 
results when serous cells were stimulated with heat-killed P. aeruginosa. VIP reduced GM-CSF and IL-6
secretion, but these effects were blocked by CFTRinh172 and subsequently restored by Eact ( Figure 9B ).
CFTRinh172 and Eact had no effect alone on P. aeruginosa-induced GM-CSF or IL-6 secretion ( Figure   9B ), again suggesting that an apical Cl -conductance is necessary, but not sufficient, for antiinflammatory effects of VIP. We also demonstrate a novel inverse relationship between NPY and VIP in the regulation of serous cell secretion. Our data here suggest that VIP may promote watery secretions of glands through Regardless, NPY-increased serous cell-derived cytokines likely help to drive inflammation.
DISCUSSION
Finally, our data support previous observations (124, 125) that the Cl -channel activity of CFTR is anti-inflammatory during VIP stimulation. A loss of these anti-inflammatory effects of VIP in CF patients lacking functional CFTR may contribute to the hyperinflammatory phenotypes reported (150). As we saw for Cl -and HCO3 -secretion, our data suggest that activation of TMEM16A can also compensate for loss of CFTR to restore anti-inflammatory effects of VIP, suggesting another possible benefit to targeting TMEM16A in CF submucosal glands of patients who cannot benefit from CFTR potentiator and/or corrector therapies due to CFTR genotype.
METHODS
Experimental Procedures
Isolation of primary serous acinar cells, immunofluorescence, and live cell imaging of acinar cell volume, pHi (SNARF-5F), and Cl -(SPQ) was carried out as described (10-12, 47, 48) . ASL height and pH measurements and ELISAs were carried out as previously reported (92, 129, (151) (152) (153) (154) (155) (156) (157) . Bacterial growth assays were carried out as previously described (158, 159) . More detailed methods for all procedures as well as specific reagents used are provided in the Supplemental Materials.
Study Approval
Tissue 
Serous cell isolation and culture
Primary human nasal serous acinar cells were used to study Cl -/fluid and HCO3 -secretion.
Studies of human turbinate submucosal gland serous cells are directly relevant to the understanding of mechanisms of CRS, particularly CF-related CRS (160), and turbinate gland serous cells approximate gland serous cells from the lower airway. Histology suggests that nasal airway glands are similar to tracheal/bronchial glands (161), and we have established that pig bronchial serous cell responses are identical to human turbinate serous cells (11, 12) . Working with human cells has important advantages over mice, as data from intact glands (19, 162, 163) and our own studies (10-12, 46-48) have established important differences between mouse serous cells and those from pigs and humans.
Patients undergoing medically indicated sinonasal surgery were recruited from the Department of
Otorhinolaryngology at the University of Pennsylvania with written informed consent as previously described (151) (152) (153) (154) . Inclusion criteria were patients ³18 years of age undergoing surgery for sinonasal disease (CRS) or other procedures (e.g., trans-nasal approaches to the skull base) where tissue was classified as "control." Exclusion criteria included history of systemic inheritable disease (e.g., granulomatosis with polyangiitis or systemic immunodeficiencies) with the exception of cystic fibrosis (CF). Members of vulnerable populations were not included.
Comparisons made here between non-CF and CF cell Cl -and HCO3 -secretion are valid because SNARF and SPQ properties were identical between CF and non-CF cells, and both genotypes had identical resting [Cl -]i, resting pHi, and intracellular pHi buffering capacity (Supplemental Figures 13-14) .
For culturing, acinar cells were washed with and resuspended in 1:1 MEME plus 20% FBS, 1x
pen/strep, gentamycin (100 µg/ml), and amphotericin B (2.5 µg/ml) as described by Finkbeiner (96) . coated with human placental collagen. After confluence, the media was changed to MEME + Lonza bronchial epithelial cell culture supplements (5 µg/ml insulin, 5 µg/ml transferrin, 0.5 µg/ml hydrocortisone, 20 ng/ml triiodothyronine, 20 nM retinoic acid, 2 mg/ml BSA) but not EGF, with 2%
NuSerum. Media lacking EGF combined with the plastic type of these transwell filters was previously shown to differentiate cells into a serous phenotype (96, 164) . After 5 days of confluence, TEER reached ~300 -500 Ω•cm 2 and cells were fed with the media above lacking NuSerum on the basolateral side while the apical side was washed with PBS and exposed to air. Cells were used after 2-4 weeks at air-liquid interface. 
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